Sanofi - Product Pipeline Review - 2016 Summary Global Markets Direct's, ‘Sanofi - Product Pipeline Review - 2016', provides an overview of the Sanofi's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sanofi, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Sanofi - The report provides overview of Sanofi including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Sanofi's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Sanofi's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Sanofi's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sanofi - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sanofi's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Sanofi Snapshot 6 Sanofi Overview 6 Key Information 6 Key Facts 6 Sanofi - Research and Development Overview 7 Key Therapeutic Areas 7 Sanofi - Pipeline Review 13 Pipeline Products by Stage of Development 13 Pipeline Products - Monotherapy 14 Pipeline Products - Combination Treatment Modalities 15 Pipeline Products - Partnered Products 16 Pipeline Products - Out-Licensed Products 19 Sanofi - Pipeline Products Glance 21 Sanofi - Late Stage Pipeline Products 21 Sanofi - Clinical Stage Pipeline Products 24 Sanofi - Early Stage Pipeline Products 26 Sanofi - Drug Profiles 28 (insulin glargine + lixisenatide) 28 lixisenatide 31 mipomersen sodium 35 semuloparin sodium 37 (fexofenadine hydrochloride + phenylephrine hydrochloride) 38 avanafil 39 cabazitaxel 40 insulin lispro 42 ziv-aflibercept (recombinant) 43 fexinidazole 47 (capecitabine + cyclophosphamide) 49 alemtuzumab 50 artefenomel + ferroquine 53 ataciguat 55 efpeglenatide 56 isatuximab 58 plerixafor 60 SAR-156597 63 sotagliflozin 64 pilaralisib 66 SAR-408701 69 SAR-421869 70 SAR-422459 72 voxtalisib 74 Monoclonal Antibodies to Inhibit Abeta for Alzheimer's Disease 76 SAR-113244 77 SAR-228810 78 SAR-366234 79 SAR-407899 80 SAR-425899 81 SAR-428926 82 SAR-438335 83 SAR-438544 84 SAR-440067 85 SAR-566658 86 ACP-003 88 DCM-1 89 efpeglenatide + HM-12470 90 food allergy vaccine 91 Peptides for Tuberculosis 92 Recombinant Proteins for Pseudomonas aeruginosa Infection 93 SAR-088 95 SAR-110068 96 SAR-131675 97 SAR-156497 98 SAR-184841 99 SAR-216471 100 SAR-224 101 SAR-244181 102 SAR-296968 103 SAR-396049 104 SAR-7334 105 Small Molecule 4 for Tuberculosis 106 Small Molecule to Inhibit Beta Sliding Clamp for Tuberculosis 107 Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds 108 Monoclonal Antibodies for Infectious Disease 109 Monoclonal Antibodies for Neurodegenerative Diseases 110 Peptide for HIV and HSV Infections 111 SAR-405 112 Small Molecule 2 for Tuberculosis 113 Small Molecule 3 for Tuberculosis 114 Small Molecule for Calcific Aortic Valve Stenosis 115 Small Molecule for Duchenne Muscular Dystrophy 116 Small Molecules for Malaria 117 Small Molecules to Inhibit Protein Kinase for Undisclosed Indication 118 Vaccine for Celiac Disease 119 Vaccine for Food Allegy 2 120 Zika virus vaccine 121 Sanofi - Pipeline Analysis 122 Sanofi - Pipeline Products by Target 122 Sanofi - Pipeline Products by Route of Administration 126 Sanofi - Pipeline Products by Molecule Type 127 Sanofi - Pipeline Products by Mechanism of Action 128 Sanofi - Recent Pipeline Updates 131 Sanofi - Dormant Projects 161 Sanofi - Discontinued Pipeline Products 165 Discontinued Pipeline Product Profiles 167 Sanofi - Company Statement 178 Sanofi - Locations And Subsidiaries 179 Head Office 179 Other Locations & Subsidiaries 179 Sanofi - Key Manufacturing Facilities 194 Appendix 195 Methodology 195 Coverage 195 Secondary Research 195 Primary Research 195 Expert Panel Validation 195 Contact Us 195 Disclaimer 196
List of Tables
Sanofi, Key Information 13 Sanofi, Key Facts 13 Sanofi - Pipeline by Indication, 2016 15 Sanofi - Pipeline by Stage of Development, 2016 20 Sanofi - Monotherapy Products in Pipeline, 2016 21 Sanofi - Combination Treatment Modalities in Pipeline, 2016 22 Sanofi - Partnered Products in Pipeline, 2016 23 Sanofi - Partnered Products/ Combination Treatment Modalities, 2016 24 Sanofi - Out-Licensed Products in Pipeline, 2016 26 Sanofi - Out-Licensed Products/ Combination Treatment Modalities, 2016 27 Sanofi - Pre-Registration, 2016 28 Sanofi - Filing rejected/Withdrawn, 2016 29 Sanofi - Phase III, 2016 30 Sanofi - Phase II, 2016 31 Sanofi - Phase I, 2016 32 Sanofi - Preclinical, 2016 33 Sanofi - Discovery, 2016 34 Sanofi - Pipeline by Target, 2016 129 Sanofi - Pipeline by Route of Administration, 2016 133 Sanofi - Pipeline by Molecule Type, 2016 134 Sanofi - Pipeline Products by Mechanism of Action, 2016 135 Sanofi - Recent Pipeline Updates, 2016 138 Sanofi - Dormant Developmental Projects,2016 168 Sanofi - Discontinued Pipeline Products, 2016 172 Sanofi, Subsidiaries 186 Sanofi, Key Manufacturing Facilities 201
List of Figures
Sanofi - Pipeline by Top 10 Indication, 2016 15 Sanofi - Pipeline by Stage of Development, 2016 20 Sanofi - Monotherapy Products in Pipeline, 2016 21 Sanofi - Combination Treatment Modalities in Pipeline, 2016 22 Sanofi - Partnered Products in Pipeline, 2016 23 Sanofi - Out-Licensed Products in Pipeline, 2016 26 Sanofi - Pipeline by Top 10 Target, 2016 129 Sanofi - Pipeline by Route of Administration, 2016 133 Sanofi - Pipeline by Top 10 Molecule Type, 2016 134 Sanofi - Pipeline Products by Top 10 Mechanism of Action, 2016 135
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.